



00-00000000



191829

**CAREFIRST - MD EXCHANGE 5T  
Nuedexta (HMF)**

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS/Caremark at 888-836-0730. Please contact CVS/Caremark at 855-582-2022 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Nuedexta (HMF).

**Patient Name:** \_\_\_\_\_ **Date:** 11/29/2023  
**Patient ID:** \_\_\_\_\_ **Patient Date Of Birth:** \_\_\_\_\_  
**Patient Group No:** \_\_\_\_\_ **Patient Phone:** \_\_\_\_\_ **Physician Name:** \_\_\_\_\_  
**NPI#:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_  
**Physician Office Telephone:** \_\_\_\_\_  
**Physician Office Address:** \_\_\_\_\_

**Drug Name (select from list of drugs shown)**

Nuedexta (dextromethorphan  
quinidine)

**Quantity:** \_\_\_\_\_ **Frequency:** \_\_\_\_\_ **Strength:** \_\_\_\_\_  
**Route of Administration:** \_\_\_\_\_ **Expected Length of Therapy:** \_\_\_\_\_  
**Diagnosis:** \_\_\_\_\_ **ICD Code:** \_\_\_\_\_

**Comments:** \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

**Please check the appropriate answer for each applicable question.**

- |   |                            |                            |
|---|----------------------------|----------------------------|
| 1. Does the patient have a diagnosis of pseudobulbar affect (PBA)?  | Y <input type="checkbox"/> | N <input type="checkbox"/> |
| 2. Is this request for continuation of therapy?   | Y <input type="checkbox"/> | N <input type="checkbox"/> |
| 3. Has the patient has achieved or maintained a decrease in pseudobulbar affect (PBA) episodes since starting the requested drug? | Y <input type="checkbox"/> | N <input type="checkbox"/> |

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

**Prescriber (Or Authorized) Signature and Date**

Effective July 1, 2015, Maryland law will require providers to submit pharmaceutical preauthorization requests electronically. To use ePA, either contact your electronic health record vendor or visit [www.covermymeds.com/epa/caremark](http://www.covermymeds.com/epa/caremark)